Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Ventrix's VentriGel™ Demonstrates Potential to Prevent Heart Failure Following Heart Attack
Pre-clinical results showing safety and effectiveness published in Science Translational Medicine

SAN DIEGO, Feb. 20, 2013 /PRNewswire/ -- Ventrix, Inc. announced today that its VentriGel cardiac repair scaffold safely and effectively mitigated left ventricular remodeling and improved cardiac function in pigs after myocardial infarction, or heart attack. The findings, made during pre-clinical studies, were published today in the journal Science Translational Medicine. Based on these and other results, Ventrix will initiate a first-in-man clinical trial for VentriGel later this year.

"These results give us strong validation that VentriGel has the potential to prevent the development of congestive heart failure in patients who are recovering from heart attack," said Adam Kinsey, Ph.D., CEO of Ventrix. "We will continue to develop VentriGel for this indication, for which there is a very acute need and large market potential."

As medical management and surgical tools have advanced, more and more patients are surviving heart attacks. However, damage to the heart during myocardial infarction can lead to a growth of dense scar tissue which cannot contribute to the pumping function of the heart. Over time, the heart wall will thin, and the heart fails, and the five-year survival rate for heart failure is only 50%. Currently, the only successful treatments for end-stage heart failure are total heart transplant and left ventricular assist devices.

In the study, the VentriGel scaffold was injected into pigs two weeks following heart attack via a minimally-invasive catheter. Three months after injection, more cardiac muscle and less scar tissue was found in the VentriGel-treated group compared to controls that did not receive VentriGel. This led to significant improvements in contractility and cardiac function and prevented heart failure in treated animals.  Ejection fraction, one measure of cardiac function, was significantly greater after delivery of VentriGel compared to controls (74% versus 43%, p < 0.01).  The global wall motion index, a measure of regional cardiac function, was significantly reduced (p < 0.05) by approximately 21% compared to controls, indicating an improvement in the contractility of the heart.

"After a myocardial infarction, patients who develop left ventricular dysfunction are at high risk for having another heart attack, and ultimately developing heart failure. These encouraging results suggest great therapeutic potential for VentriGel," said Dr. Anthony N. Demaria, former President of the American College of Cardiology, Professor of Medicine at the University of California, San Diego, and advisor to Ventrix.

About Myocardial Infarction
Approximately 785,000 new heart attack cases occur each year in the United States. Many of those patients will develop left ventricular dysfunction, a weakening of the heart's ability to effectively pump blood. According to the American Heart Association, at least 22 percent of men and 46 percent of women will develop heart failure—a debilitating and burdensome condition—within six years of their first heart attack.

About VentriGel
VentriGel is a biomaterial scaffold designed specifically for the repair of damaged myocardium. It is injected via catheter in a minimally-invasive procedure that does not require surgery or general anesthesia. The first-in-class, off-the-shelf, injectable biomaterial scaffold  is built on technology licensed from the University of California, San Diego.

About Ventrix
Founded in 2009, Ventrix is a San Diego-based company developing solutions for repair of the heart. Currently, the organization is focused on delivering a scaffold for cardiac repair following myocardial infarction.

SOURCE Ventrix, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
Be Among the First 100 to Attend & Receive a Smart Beacon. The Physical Web is an open web project within the Chrome team at Google. Scott Jenson leads a team that is working to leverage the scalability and openness of the web to talk to smart devices. The Physical Web uses bluet...
Yahoo CIO Mike Kail will present a session on DevOps at the 3rd International DevOps Summit, November 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Mike brings more than 23 years of IT operations experience with a focus on highly scalable architectures to Y...
The industry is heated with debates on whether adopting private or public cloud is the smartest, best, cheapest, you name it choice. But this debate is missing the mark. Businesses shouldn't be discussing public vs. private, but rather how can they make the two work together to t...
14th International Cloud Expo, held on June 10–12, 2014 at the Javits Center in New York City, featured three content-packed days with a rich array of sessions about the business and technical value of cloud computing, Internet of Things, Big Data, and DevOps led by exceptional s...
People often ask how Qubell is different from Chef, Puppet, OpenShift, Docker, Heat, Ansible, Mesos, Kubernetes or some other hip product du jour. Like any comparison of apples to oranges, the answer involves a surprisingly deep investigation into botanical conventions, differenc...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News

DALLAS, Aug. 30, 2014 /PRNewswire-iReach/ -- The mobile cloud market is fast gaining momentum pri...